Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

ISSN
1471-2466
Date Issued
2022-06-28
Author(s)
Blasi, Miriam
Eichhorn, Martin E.
Christopoulos, Petros
Winter, Hauke
Heußel, Claus Peter
Herth, Felix J.
Kriegsmann, Katharina
Kriegsmann, Mark
Stenzinger, Albrecht
Bischoff, Helge
Thomas, Michael
Kuon, Jonas
DOI
10.1186/s12890-022-02043-6
Abstract
Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population.